argenx (NASDAQ:ARGX – Get Free Report) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect argenx to post earnings of $0.10 per share for the quarter.
argenx (NASDAQ:ARGX – Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. During the same period last year, the company earned ($1.69) EPS. On average, analysts expect argenx to post $0 EPS for the current fiscal year and $5 EPS for the next fiscal year.
argenx Price Performance
NASDAQ ARGX opened at $557.92 on Thursday. The company has a market cap of $33.16 billion, a P/E ratio of -98.57 and a beta of 0.63. argenx has a 12 month low of $327.73 and a 12 month high of $571.97. The company has a 50-day moving average of $533.68 and a 200-day moving average of $457.45.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on ARGX
argenx Company Profile
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than argenx
- Why Are These Companies Considered Blue Chips?
- A $1.75 Billion Gamble: Can Lucid Ignite Growth?
- Stock Dividend Cuts Happen Are You Ready?
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- Best Stocks Under $10.00
- 3 Undervalued Technology Stocks With Big Rebound Potential
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.